Alsertib (MLN8237) and Brentuximab Vedotin for Relapsed/Refractory CD30-Positive Lymphomas and Solid Malignancies (AD3LE)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT02780011 |
|
Recruitment Status :
Withdrawn
(lack of funding)
First Posted : May 23, 2016
Last Update Posted : July 27, 2018
|
Sponsor:
Eric Bernicker, MD
Collaborators:
Millennium Pharmaceuticals, Inc.
The Methodist Hospital Research Institute
Information provided by (Responsible Party):
Eric Bernicker, MD, The Methodist Hospital Research Institute
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
Study was withdrawn before participants were enrolled.
| Recruitment Status : | Withdrawn |
|---|---|
| Estimated Primary Completion Date : | September 2018 |
| Estimated Study Completion Date : | September 2018 |